Vasomotor symptoms fade, but genitourinary syndrome of menopause (GSM) does not. An estimated 84% of postmenopausal women experience GSM within six years of menopause, yet roughly half receive no treatment and approximately 60% report their clinician has never raised the topic. Left untreated, GSM is chronic and progressive, driving recurrent UTIs, dyspareunia, urinary urgency, and meaningful declines in quality of life.
Course Features:
– 3 video lectures,
– 1 patient case explored,
– 1 downloadable resource.
Content Covered:
This concise microlearning series equips primary care clinicians to close the GSM care gap through three short, clinically focused videos:
Video 1: The dual hormonal decline of estrogen and androgen that drives GSM pathophysiology.
Video 2: Efficient screening in clinical practice across the three symptom domains: genital, sexual, and urological.
Video 3: Shared decision-making and presumptive language to individualize treatment selection and support adherence.
Each video runs approximately five to seven minutes and features practice-ready patient dialogue, a running case, and guidance on menopause and genitourinary health.
On completion, learners will be better able to recognize GSM, screen all perimenopausal and postmenopausal patients, and apply a shared decision-making framework to select evidence-based therapy: lubricants and moisturizers, vaginal estrogen, vaginal prasterone, or oral ospemifene.
This program has received an unrestricted educational grant or in-kind support from Lupin Pharma Canada.